RxDoctor Payments Data

Stefania Fynn-Aikins, NP

Psychiatric/Mental Health · Amherst, NYNPI 1508955402

Payments from drug & device makers

$6,182in general payments, 2019–2025

Across 164 payments — averaging $37.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$978
  • Alkermes, Inc.$895
  • Otsuka America Pharmaceutical, Inc.$499
  • Axsome Therapeutics, Inc.$490
  • Vanda Pharmaceuticals Inc.$457
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$6,170100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,182 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$27,397
Medicare patients
80
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Wellbutrin XlBupropion Hcl11$27,234
VraylarCariprazine Hcl11$15,103
RexultiBrexpiprazole12$14,500
TrintellixVortioxetine Hydrobromide20$12,905
Bupropion XlBupropion Hcl222$5,493
Aripiprazole120$4,538
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$4,089
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine75$4,080
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine91$3,432
Duloxetine Hcl227$3,417
Alprazolam501$2,998
Clomipramine Hcl22$2,920
Fluoxetine Hcl138$2,471
Fluvoxamine Maleate17$2,327
Ziprasidone Hcl40$2,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,072$15,10311 claims
Otsuka America Pharmaceutical, Inc.Rexulti$499$14,50012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$105$12,90520 claims
Almatica Pharma LLCSertraline Hcl$31$1,665120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →